Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AZD-0120 by Gracell Biotechnologies for Refractory Multiple Myeloma: Likelihood of Approval
AZD-0120 is under clinical development by Gracell Biotechnologies and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
Data Insights
AZD-0120 by Gracell Biotechnologies for Relapsed Multiple Myeloma: Likelihood of Approval
AZD-0120 is under clinical development by Gracell Biotechnologies and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...